A mandatory period of dual-antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is imperative after coronary artery bare-metal or drug-eluting stent (DES) implantation
A mandatory period of dual-antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is imperative after coronary artery bare-metal or drug-eluting stent (DES) implantation (1) . The need for mandatory DAPT after DES implantation is determined by the need to protect the stented vascular segment while vascular healing and neoendothelial coverage are ongoing, a process that seems to be completed between 3 and 9 months with newgeneration devices and is dependent on DES type (1) . After this initial period, DAPT may be prolonged, with the aim of providing broader atherothrombotic protection from events arising outside the stented vascular segment (2) .
From another point of view, percutaneous coronary intervention (PCI) for stable coronary artery disease has been associated with a mandatory DAPT period of 3 to 6 months; conversely, the consensus is that 1 year of mandatory DAPT should be administered after PCI for acute coronary syndromes (3).
However, the cardiac ischemic protection achieved with intense prolonged platelet inhibition has a risk for clinically significant bleeding, which affects subsequent morbidity and possibly mortality (4).
The optimal duration of DAPT after DES has been investigated in more than 10 randomized controlled trials and several meta-analyses (3), including a very large trial focused on very late stent thrombosis.
Interpretation of the available evidence on this subject should be cautious, because indiscriminate long and Sanofi. Dr. Giustino has reported that he has no relationships relevant to the contents of this paper to disclose. Angiographic complexity and procedural success may be the next parameters to introduce in the equation to better tailor the duration and potency of DAPT after coronary stenting.
